A61K 2039/575
Humoral response
Official title: {humoral response}
A61K2039/575 (Humoral response) appears on 1,342 US grants and 2,943 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,342
- Published applications
- 2,943
- Assignees
- 1,220
- Inventors
- 6,168
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 4 |
| 2003 | 1 | 5 |
| 2004 | 3 | 9 |
| 2005 | 3 | 10 |
| 2006 | 0 | 13 |
| 2007 | 3 | 11 |
| 2008 | 0 | 12 |
| 2009 | 7 | 28 |
| 2010 | 9 | 29 |
| 2011 | 11 | 36 |
| 2012 | 14 | 34 |
| 2013 | 18 | 55 |
| 2014 | 45 | 67 |
| 2015 | 48 | 97 |
| 2016 | 73 | 160 |
| 2017 | 91 | 202 |
| 2018 | 118 | 151 |
| 2019 | 132 | 135 |
| 2020 | 127 | 155 |
| 2021 | 102 | 176 |
| 2022 | 105 | 210 |
| 2023 | 94 | 327 |
| 2024 | 113 | 398 |
| 2025 | 129 | 375 |
| 2026 | 77 | 244 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
Most cited
By later US patents
- GITR-binding antibodies141US 7,812,135 B2TolerRx, Inc. · 2010
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies121US 8,388,967 B2GITR, Inc. · 2013
- Zika virus RNA vaccines108US 10,124,055 B2ModernaTX, Inc. · 2018
- Alphavirus vectors and virosomes with modified HIV genes for use in vaccines101US 6,783,939 B2AlphaVax, Inc. · 2004